FDA requests removal of prescription opioid from the market
June 9, 2017
Washington, D.C. – For the first time, the U.S. Food and Drug Administration is requesting the removal of a prescription opioid from the market due to public health consequences from abuse. The FDA is requesting Endo Pharmaceuticals remove Opana ER (oxymorphone hydrochloride) …
